Founded in 2018, Celadon is a UK based pharmaceutical company with a primary focus on cultivating medicinal cannabis utilising indoor hydroponics technology in the highly regulated UK market. Celadon will not only specialise in the manufacture of active pharmaceutical ingredients but will also participate in the further research of cannabinoids for use in other ailments such as autism and multiple sclerosis.
Celadon are in the advanced stage of the application process to receive licences from the Home Office and MHRA and therefore expects to be one of the first businesses licenced under the new 2018 UK legislation to be able to grow and supply medicinal cannabis with a high THC content in the UK, allowing it an opportunity to become the dominant player in what is expected to be a large and fast-growing UK market.
In recent years an increasing number of patients have been using cannabinoids to treat a variety of conditions including chronic pain, cancer pain, anxiety disorders, sleep apnoea and neurological disorders. In the UK, the majority of these patients are buying their cannabis on the black market. A limited number of other users are buying their cannabis through the existing legal “specials” market. Although administrative complexities related to the importation of cannabis from outside the UK means this is highly inefficient.
Imperial College research suggests that chronic pain (defined as pain that persists for 6 months or more) affects c.28 million people in the UK; of those, up to 8 million people suffer severe chronic pain. These patients are currently treated using opioids (which are the most common treatments utilised), paracetamol, anti-neuropathic agents and non-steroidal anti-inflammatory drugs, all of which are expensive and have damaging side effects. The UK Government has estimated that of the c. 8 million people in the UK with chronic pain, c. 3 million would be eligible for a prescription of cannabinoids on the NHS.
Kings College London estimates that 1.4 million – 3 million people in the UK are currently using cannabis to treat pain by acquiring it on the black market.
Celadon has a state-of-the-art facility located in the Midlands, UK, that comprises an EU-GMP designed laboratory and a large growing facility that is in the final stages of being approved for licences from the Home Office and the MHRA.
The cultivation facility is designed as an indoor, closed-loop hydroponic system to ensure cannabis plants are cultivated under highly specific climate, light and irrigation control at all time.
With the use of technology, Celadon is in the process of designing a programme of “pheno hunting” to allow Celadon to develop further stable seed genetics and flower for the medicinal market.
Whether you are a customer, health care professional, investor or a job seeker, you can find out more information about Celadon by visting us on our next open day.
Fill in the form to arrange your visit.
Input your search keywords and press Enter.